Corcept Therapeutics INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Investment firm Ingalls & Snyder LLC has reported a 6.8% beneficial ownership stake in Corcept Therapeutics Inc.
NASDAQ
The Vanguard Group has filed an amendment to its Schedule 13G, reporting zero beneficial ownership in Corcept Therapeutics Inc. following an internal realignment.
NASDAQ
Renaissance Technologies LLC and its parent company have reported a 5.47% beneficial ownership stake in Corcept Therapeutics Incorporated.
NASDAQ
SCHEDULE 13G/A: BlackRock Maintains Significant Stake in Corcept Therapeutics, Reports 10.9% Ownership
BlackRock, Inc. has filed an Amendment No. 4 to its Schedule 13G, disclosing a 10.9% beneficial ownership stake in Corcept Therapeutics Incorporated as of June 30, 2025.
NASDAQ
BlackRock, Inc. has filed an amended Schedule 13G, revealing a beneficial ownership of 12.7% of Corcept Therapeutics Inc.'s common stock as of March 31, 2025.
NASDAQ
Investment firm Ingalls & Snyder LLC has disclosed a passive beneficial ownership of 7.8% of Corcept Therapeutics Inc.'s common stock as of December 31, 2024.
NASDAQ
SCHEDULE 13G/A: Corcept Therapeutics CEO Joseph Belanoff Discloses Significant Beneficial Ownership Stake
Corcept Therapeutics Incorporated's CEO, Dr. Joseph K. Belanoff, has filed an amendment to his Schedule 13G, detailing his beneficial ownership of 6.3% of the company's Common Stock as of December 31, 2024.